Small molecule ACK1 inhibitor (R)-9b - third generation AR receptor - clinical trial I in 2023

Technogenesys will start a trial in 2023, be prepared:

Thus,, there is an acute need for next generation of inhibitor that can overcome Enzalutamide and Abiraterone resistance. We have identified (R)-9b as a `third generation' of AR-antagonist, which has ability to overcome Enzalutamide and abiraterone-resistant prostate cancer.

[GP24]

More details here: technogenesys.com/ack1-inhi...

[Fennelli]

My husband was on Enzalutemide for eleven months before treatment failed. Initially PSA halved but out of control blood pressure requiring three different medications to treat, and a very noticeable brain fog were the worst side effects - he had real difficulty in thinking. Fortunately since no longer taking the drug, his mental acuity has returned to normal. Muscle tone was also dramatically affected by Enzalutemide. But, he has been told that Enzalutemide works well for many patients but just does not suit everyone. Now on Lutetium 177 and very happy with the results to date. Good luck to all.